Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population

References

• Institute of Medicine. Value in Health Care: Accounting for Cost, Quality, Safety, Outcomes, and Innovation: Workshop Summary. Washington, DC: The National Academies Press; 2010.
   Google Scholar
• Deodhar A, Mittal M, Reilly P, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol. 2016;35(7):1769–1776. doi:10.1007/s10067-016-3231-z26987341
   PubMed Web of Science ®Google Scholar
• Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010;69(1):222–225. doi:10.1136/ard.2008.10250919293160
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–1780. doi:10.1038/ajg.2014.24225155227
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi:10.1056/NEJMoa05051616339095
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38(10):1236–1247. doi:10.1111/apt.1249924134498
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68(6):823–827. doi:10.1136/ard.2008.09001918593759
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37. doi:10.1002/art.2151916385520
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi:10.1016/S0140-6736(02)08512-412047962
   PubMed Web of Science ®Google Scholar
• Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–2521. doi:10.1185/03007995.2014.96936825252590
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Lionetti P, Blandizzi C, et al. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol. 2014;27(1 Suppl):11–32. doi:10.1177/03946320140270S10224774504
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi:10.1136/pgmj.2006.05268817403952
   PubMed Web of Science ®Google Scholar
• Olivieri I, Cortesi PA, de Portu S, et al. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol. 2016;34(1):68–75.26633622
   PubMed Web of Science ®Google Scholar
• Staples MP, March L, Lassere M, Reid C, Buchbinder R. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association database. Rheumatology (Oxford). 2011;50(1):166–175. doi:10.1093/rheumatology/keq32220929971
   PubMed Web of Science ®Google Scholar
• Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2006;6(2):99–107. doi:10.1517/14712598.6.2.9916436036
   PubMed Web of Science ®Google Scholar
• Lapadula G, Marchesoni A, Armuzzi A, et al. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27(1 Suppl):33–48. doi:10.1177/03946320140270S10324774505
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Impact of TNF-alpha antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol. 2013;148(3):243–248.23670060
   PubMed Web of Science ®Google Scholar
• Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-alpha inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19(27):4344–4350. doi:10.3748/wjg.v19.i27.434423885145
   PubMed Web of Science ®Google Scholar
• Wentworth BJ, Buerlein RCD, Tuskey AG, Overby MA, Smolkin ME, Behm BW. Nonadherence to biologic therapies in inflammatory bowel disease. Inflamm Bowel Dis. 2018. doi:10.1093/ibd/izy102
   Web of Science ®Google Scholar
• Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19(7):1528–1533. doi:10.1097/MIB.0b013e31828132cb23518810
   PubMed Web of Science ®Google Scholar
• Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Ther. 2009;26(10):936–946. doi:10.1007/s12325-009-0069-719838649
   PubMed Web of Science ®Google Scholar
• Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Adv Ther. 2011;28(8):671–683. doi:10.1007/s12325-011-0048-721818671
   PubMed Web of Science ®Google Scholar
• Perry J, Chen A, Kariyawasam V, et al. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intest Res. 2018;16(4):571–578. doi:10.5217/ir.2018.0003330301333
   PubMed Web of Science ®Google Scholar
• Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication non-adherence after discharge from a general internal medicine service. PLoS One. 2013;8(5):e61735. doi:10.1371/journal.pone.006173523658698
   PubMed Web of Science ®Google Scholar
• Harnett J, Wiederkehr D, Gerber R, Gruben D, Bourret J, Koenig A. Primary nonadherence, associated clinical outcomes, and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2016;22(3):209–218. doi:10.18553/jmcp.2016.22.3.20927003550
   PubMed Web of Science ®Google Scholar
• Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–290. doi:10.1007/s11606-010-1253-920131023
   PubMed Web of Science ®Google Scholar
• Shah NR, Hirsch AG, Zacker C, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392–396. doi:10.1038/ajh.2008.36719180061
   PubMed Web of Science ®Google Scholar
• Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44(5 Pt 1):1640–1661. doi:10.1111/j.1475-6773.2009.00989.x19500161
   PubMed Web of Science ®Google Scholar
• Hohl CM, Abu-Laban RB, Brubacher JR, et al. Adherence to emergency department discharge prescriptions. CJEM. 2009;11(2):131–138.19272214
   PubMedGoogle Scholar
• Stockl KM, Shin JS, Gong S, Harada AS, Solow BK, Lew HC. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care. 2010;16(2):139–144.20148619
   PubMed Web of Science ®Google Scholar
• Stockl KM, Shin JS, Lew HC, et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm. 2010;16(8):593–604. doi:10.18553/jmcp.2010.16.8.59320866164
   PubMed Web of Science ®Google Scholar
• Ali M, Schifano F, Robinson P, et al. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: a randomized controlled study. Diabet Med. 2012;29(9):e326–e333. doi:10.1111/j.1464-5491.2012.03725.x22672148
   PubMed Web of Science ®Google Scholar
• Al Hayek AA, Robert AA, Al Dawish MA, Zamzami MM, Sam AE, Alzaid AA. Impact of an education program on patient anxiety, depression, glycemic control, and adherence to self-care and medication in type 2 diabetes. J Family Community Med. 2013;20(2):77–82. doi:10.4103/2230-8229.11476623983558
   PubMedGoogle Scholar
• Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711–725. doi:10.2147/PPA.S10117527175071
   PubMed Web of Science ®Google Scholar
• HUMIRA Patient Support Program. Available from https://www.humira.com/humira-complete. Updated August 18, 2019 Accessed August 21, 2019.
   Google Scholar
• Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859–867. doi:10.18553/jmcp.2017.1627228737994
   PubMedGoogle Scholar
• Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648–658. doi:10.18553/jmcp.2009.15.8.64819803554
   PubMed Web of Science ®Google Scholar
• Starner CI, Alexander GC, Bowen K, Qiu Y, Wickersham PJ, Gleason PP. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums. Health Aff (Millwood). 2014;33(10):1761–1769. doi:10.1377/hlthaff.2014.049725288420
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.16224307
   PubMed Web of Science ®Google Scholar
• Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J Manag Care Spec Pharm. 2016;22(2):122–130. doi:10.18553/jmcp.2016.1426127015251
   PubMed Web of Science ®Google Scholar
• Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153(10):633–640. doi:10.7326/0003-4819-153-10-201011160-0000521079218
   PubMed Web of Science ®Google Scholar
• Silverman E. Increased abandonment of prescriptions means less control of chronic conditions. Manag Care. 2010;19(6):33–36.
   Google Scholar
• Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3 Suppl):46s–51s. doi:10.1200/JOP.2011.00031621886519
   PubMedGoogle Scholar
• Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.008063324312488
   PubMed Web of Science ®Google Scholar
• Marshall JK, Bessette L, Thorne C, et al. Impact of the adalimumab patient support program’s care coach calls on persistence and adherence in Canada: an observational retrospective cohort study. Clin Ther. 2018;40(3):415–429.e416. doi:10.1016/j.clinthera.2018.02.00129519714
   PubMed Web of Science ®Google Scholar
• Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770–779. doi:10.18553/jmcp.2019.1844331081461
   PubMed Web of Science ®Google Scholar
• Derose SF, Green K, Marrett E, et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med. 2013;173(1):38–43. doi:10.1001/2013.jamainternmed.71723403978
   PubMed Web of Science ®Google Scholar